Clinical Trial

Auto-antibody Dosage From Blood Spots for Diagnosis of Type 1 Diabetes and Celiace Disease

Study acronym: CELDI
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Early diagnosis of type 1 diabetes and celiac disease is very useful, allows early therapy and prevents deaths from the onset of diabetic ketoacidosis. This is a pilot study on screening of autoantibodies of type 1 diabetes and celiac disease in tuscany patients. The study aims to evaluate the concordance between the screening results obtained using two different matrix (blood drop spots on card and serum) in the search for autoantibodies for celiac disease and for type 1 diabetes. Moreover, it will be evaluated the feasibility and acceptability of the screening on a sample of the population enrolled in the territory through the participation of pediatricians.
Trial Details
NCT Number NCT06849622
Lead Sponsor Meyer Children's Hospital IRCCS
Conditions Celiac Disease in Children, Diabetes Mellitus, Type I, Screening
Enrollment 1,500 participants
Start Date 2024-11-04
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-27